Consistent with this, Tomioka and colleagues [42], [43] reported that treatment with the recombinant HGF antagonist NK4 inhibited orthotopic tumor growth and dissemination in vivo and decreased MVD in pancreatic tumors. Here, HGF is linked to neoplasm.